Has Akshay Khandelwal, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,356 in general payments to Akshay Khandelwal, MD across 19 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Akshay Khandelwal, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Akshay Khandelwal, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Akshay Khandelwal, MD

Interventional Cardiology · Wexford, PANPI 1053513986

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Edwards Lifesciences at 24.5% of the total. Reporting peaked in 2024 at $441 and has fallen 68.2% since, to $140 in 2025. That places this record below the midpoint for interventional cardiology clinicians in PA, where the typical reported total is $6,486.

$1,356in general payments, 2019–2025

Across 19 payments — averaging $71.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Edwards Lifesciences$332
Inari Medical, Inc.$294
Medtronic$130
Abiomed$129
Philips North America LLC$128
Cook Medical LLC$113
plus $230 from 6 others

$9,149in research payments, 2019–2025

Across 7 payments — averaging $1307.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Abbott$9K

What the payments were for

Food & beverage$1,356100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Edwards Lifesciences	2	$332
Inari Medical, Inc.	2	$294
Medtronic	1	$130
Abiomed	1	$129
Philips North America LLC	3	$128
Cook Medical LLC	1	$113
Terumo Medical Corporation	1	$62
Impulse Dynamics (USA) Inc.	2	$47
Boston Scientific	2	$46
Abbott	2	$43
Cardiovascular Systems Inc.	1	$18
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

FLOWTRIEVER CATHETER, S$294
CT THROMBECTOMY SYSTEM KIT$294
Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$182
EVOQUE$150
COREVALVE EVOLUT R$130
Impella$129
Zilver PTX$113

How this compares

$1,356 in reported general payments places this provider in the 10th percentile of 281 interventional cardiology providers in Pennsylvania.

See all interventional cardiology providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$24,383

Medicare patients

111

Services billed

189

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	94	$88,336
EntrestoSacubitril/Valsartan	34	$38,323
Repatha SureclickEvolocumab	26	$16,332
Metoprolol Succinate	154	$1,792
Rosuvastatin Calcium	97	$1,221
Diltiazem 24hr Er (Cd)Diltiazem Hcl	43	$779
Atorvastatin Calcium	79	$512
Carvedilol	57	$355
Losartan Potassium	36	$338
ClopidogrelClopidogrel Bisulfate	21	$258
Lisinopril	22	$242
Amlodipine Besylate	70	$206
Valsartan	21	$174
Spironolactone	30	$107
Metoprolol Tartrate	25	$88

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Wexford

Samer AzouzWexford$160K
Nishant SethiScranton$1.3M
Matthew BeckerErie$1M
William GrayWynnewood$753K
Jon GeorgePhiladelphia$637K
Shailendra SinghAllentown$470K
Sanjog KalraPhiladelphia$444K
James HarveyChambersburg$442K
Taisei KobayashiPhiladelphia$384K
Antonis PratsosBroomall$377K

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →